CRK and chronic myelogenous leukemia, BCR-ABL1 positive: While this indicates that under some conditions Abl-mediated Crk phosphorylation may inhibit oncogenicity, it does raise a paradox as to whether Imatinib (Gleevec), may have side effects when used to treat CML.